Form 4: Moderna's Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Chief Legal Officer of Moderna, Shannon Thyme Klinger, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On March 7, 2025, Shannon Thyme Klinger, the Chief Legal Officer of Moderna, engaged in transactions involving Moderna's common stock and restricted stock units.
- Klinger acquired 1,139 shares of common stock through the conversion of restricted stock units.
- Klinger disposed of 551 shares of common stock to satisfy tax withholding obligations at a price of $34.3 per share.
- Following these transactions, Klinger directly owns 25,612 shares of Moderna common stock.
- Klinger also reports ownership of 1,139 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by an insider, with no inherent positive or negative sentiment. It simply reflects the execution of previously granted stock options and tax obligations.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key personnel and their sentiment towards the company's stock.
Key Dates
| Date | Description |
|---|---|
| June 7, 2022 | 25% of the shares subject to the restricted stock unit award vested. |
| March 7, 2025 | Date of the reported transactions involving common stock and restricted stock units. |
| March 10, 2025 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.